Prediction of PPAR-α ligand-mediated physiological changes using gene expression profiles

被引:0
|
作者
Frederiksen, KS [1 ]
Wulff, EM
Sauerberg, P
Mogensen, JP
Jeppesen, L
Fleckner, J
机构
[1] Novo Nordisk AS, Dept Mol Genet, DK-2880 Bagsvaerd, Denmark
[2] Med Chem Res 3, Dept Pharmacol Res 2, DK-2760 Malov, Denmark
[3] Novo Nordisk Pk, DK-2760 Malov, Denmark
关键词
dyslipidemia; pharmacodynamics; peroxisome proliferator-activated receptor-alpha in vivo activation; transcriptional profiling;
D O I
10.1194/jlr.D300239-JLR200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Peroxisome proliferator-activated receptor (PPAR)-alpha controls the transcription of a variety of genes involved in lipid metabolism and is the target receptor for the hypolipidemic drug class of fibrates. In the present study, the molecular and physiological effects of seven different PPAR-activating drugs have been examined in a rodent model of dyslipidemia. The drugs examined were selected to display varying potencies and efficacies toward PPAR-alpha. To help elucidate the link between the gene regulation elicited by PPAR-alpha ligands and the concomitant physiological changes, we have used cDNA microarray analysis to identify smaller gene sets that are predictive of the function of these ligands. A number of genes showed strong correlations to the relative PPAR-alpha efficacy of the drugs. Furthermore, using multivariate analysis, a strong relationship between the drug-induced triglyceride lowering and the transcriptional profiles of the different drugs could be found.-Frederiksen, K. S., E. M. Wulff, P. Sauerberg, J. P. Mogensen, L. Jeppesen, and J. Fleckner. Prediction of PPAR-alpha ligand-mediated physiological changes using gene expression profiles.
引用
收藏
页码:592 / 601
页数:10
相关论文
共 50 条
  • [31] Ligand-mediated anticodon conformational changes occur during tRNA methylation by a TrmD methyltransferase
    Watts, JM
    Gabruzsk, J
    Holmes, WM
    BIOCHEMISTRY, 2005, 44 (17) : 6629 - 6639
  • [32] PPAR-γ down-regulates cbfa-1 mediated osteocalcin expression in osteoblast
    Shin, CS
    Jeon, MJ
    Kwon, SH
    Kim, JA
    Kim, SY
    BONE, 2002, 30 (03) : 11S - 11S
  • [33] An oligopeptide ligand-mediated therapeutic gene nanocomplex for liver cancer-targeted therapy
    Liu, M.
    Li, Z. H.
    Xu, F. J.
    Lai, L. H.
    Wang, Q. Q.
    Tang, G. P.
    Yang, W. T.
    BIOMATERIALS, 2012, 33 (07) : 2240 - 2250
  • [34] Resistance to Fas/Fas ligand-mediated apoptosis and expression of survival proteins on lung fibroblasts
    Tanaka, T
    Hagimoto, N
    Maeyama, T
    Miyazaki, H
    Kunitake, R
    Kawasaki, M
    Matsuba, T
    Kuwano, K
    Hara, N
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A197 - A197
  • [35] UDoGeC: Essential Protein Prediction Using Domain And Gene Expression Profiles
    Shabnam, Fathima C. B.
    Izudheen, Sminu
    PROCEEDINGS OF THE 6TH INTERNATIONAL CONFERENCE ON ADVANCES IN COMPUTING AND COMMUNICATIONS, 2016, 93 : 1003 - 1009
  • [36] PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
    Ajay Chawla
    Yaacov Barak
    Laszlo Nagy
    Debbie Liao
    Peter Tontonoz
    Ronald M. Evans
    Nature Medicine, 2001, 7 : 48 - 52
  • [37] PPAR-γ represses interferon-γ gene expression by sequestration of CBP/p300
    Zhang, X
    Young, HA
    FASEB JOURNAL, 2004, 18 (05): : A1138 - A1138
  • [38] PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
    Chawla, A
    Barak, Y
    Nagy, L
    Liao, D
    Tontonoz, P
    Evans, RM
    NATURE MEDICINE, 2001, 7 (01) : 48 - 52
  • [39] Opposite regulation of PPAR-α and -γ gene expression by both their ligands and retinoic acid in brown adipocytes
    Valmaseda, A
    Carmona, MC
    Barberá, MJ
    Viñas, O
    Mampel, T
    Iglesias, R
    Villarroya, F
    Giralt, M
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1999, 154 (1-2) : 101 - 109
  • [40] Structural changes of glycosaminoglycans from human vascular smooth muscle, induced by the PPAR-α ligand, fenofibrate.
    Nigro, J
    Ivey, ME
    Jennings, GL
    Little, PJ
    DIABETOLOGIA, 2003, 46 : A52 - A52